| Autor: |
Smekens L; Service d'oncologie, Hôpitaux Universitaires de Genève, Geneva, Switzerland.; Equal contribution., Genoud V; Service d'oncologie, Hôpitaux Universitaires de Genève, Geneva, Switzerland.; Center for Translational Research in Onco-Haematology, University of Geneva, Geneva, Switzerland.; Equal contribution., Usdin N; Service d'oncologie, Hôpitaux Universitaires de Genève, Geneva, Switzerland.; Equal contribution., Ben Aïssa A; Service d'oncologie, Hôpitaux Universitaires de Genève, Geneva, Switzerland. |
| Jazyk: |
angličtina |
| Zdroj: |
Praxis [Praxis (Bern 1994)] 2023; Vol. 112 (3), pp. 160-171. |
| DOI: |
10.1024/1661-8157/a003976 |
| Abstrakt: |
Immunotherapy with immune checkpoint inhibitors (ICI) is administered in different cancer types and can lead to a wide range of immune-related adverse events including toxicity in vital organs such as the lungs, the kidneys, and the heart. The main hypothesis suggests an overactivation of the immune cells in the different organs. Whereas immune-related cardiotoxicity is very rare but life threatening, ICI-induced acute kidney injury and pneumonitis are more frequent but in general less severe. Renal toxicity corresponds in more than 90% to an acute tubulo-interstitial nephritis. Checkpoint inhibitors pneumonitis is diagnosed mainly on respiratory symptoms with new radiological features, especially under the form of a cryptogenic organising pneumonia. Cardiotoxicity is predominantly marked by myocarditis but also pericarditis and arrhythmias, among others. Early recognition, temporary or definitive cessation of ICI therapy and rapid initiation of high-dose corticosteroids are the cornerstones of the management, which must to be multidisciplinary in a specialised center. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|
